Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Inclusion Criteria: * Healthy male subjects aged18 and 50 years inclusive; BMI between 18 and 28 kg/m2 and body weight between 50 and 80 kg. * Physical examinations and vital signs are normal or abnormal without clinical significance. * Abdominal color Doppler ultrasound, laboratory tests, etc. are normal or abnormal without clinical significance. Exclusion Criteria: * Any current or history of severe allergic reaction to foods or drugs and History of allergy to study products. * Having severe injuries or surgery or fractures within 4 weeks before enrollment,or to receive surgery during the study. * Having clinically significantclinical history abnormalities or other clinically indicated diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, mental or cardiovascular diseases). * Having malignant tumor (excluding basal cell carcinoma who has undergone resection). * Having clinically significant chronic or acute infections at screening/incorporation; or active infections,Includes acute and chronic infections as well as local infections (bacteria, viruses, parasites, fungi or other opportunities) Sexually infected pathogen). * Having a history of tuberculosis or latent tuberculosis or clinical manifestations suspected of being tuberculosis(including But not limited to tuberculosis). * Having been exposed to tuberculosis or/and suspected tuberculosis symptoms and/or signs within 3 months before screening. * Having used simponi,or any anti-tumor necrosis factor (TNF-α) biologic preparation or any biological products within 6 months before enrollment or monoclonal antibodies within a month. * Having used drugs within 30 days before enrollment (including but not limited to prescription drugs, Chinese medicine, non-prescription drugs). * Having vaccinated active / attenuated vaccine within 12 weeks before screening or planned to vaccinate active /attenuated vaccine the during the study. * Having a history of hypertension or systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ at screening/inclusion90 mmHg, and it is judged abnormalities with clinical significance. * Electrocardiogram (ECG) examination abnormalities with clinical significance; * Having positive detection of golimumab anti-drug antibody (ADA) during screening. * Chest orthotopic examination abnormalities with clinical significance. * Tuberculosis enzyme-linked immunospot assay (T-SPOT. TB) positive test, * Having any alcoholic products within 24 hours prior to the use of the study drug. * A drug abuse test positive or a history of drug abuse over the past five years.